AstraZeneca says U.S. FDA approves lung cancer drug
Tuesday, July 14, 2015
Astrazeneca Plc Iressa approved by U.S. FDA.
U.S. food and drug administration has approved iressa (gefitinib) tablets, 250mg once daily, for first-line treatment of patients with metastatic non-small cell lung cancer.
Astrazeneca has partnered with qiagen to provide therascreen egfr companion diagnostic test for iressa in us.
FDA approval of Iressa is based on data from phase iv ifum 1 (iressa follow-up measure) study, assessing Iressa as a first-line treatment.
Also studying Iressa in combination with other investigational medicines, including company's anti-pd-l1 monoclonal antibody.
reuters.com
